MSB 7.69% $1.19 mesoblast limited

DREAM HF Trial Video, page-28

  1. 15,454 Posts.
    lightbulb Created with Sketch. 5535
    I do wonder if the company have been trying to tell us something ? The reference is subtle but consistent in their reporting - just sayin'


    https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program
    Accelerated Approval Program


    The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.

    Drug companies are still required to conduct studies to confirm the anticipated clinical benefit. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.



    31 January 2023
    upload_2023-2-3_10-41-44.png



    22 November 2022
    upload_2023-2-3_10-43-31.png



    31 October 2022
    upload_2023-2-3_10-44-57.png



    19 July 2022
    upload_2023-2-3_10-39-27.png
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.19
Change
0.085(7.69%)
Mkt cap ! $1.358B
Open High Low Value Volume
$1.10 $1.20 $1.09 $13.21M 11.37M

Buyers (Bids)

No. Vol. Price($)
1 15000 $1.19
 

Sellers (Offers)

Price($) Vol. No.
$1.19 75212 5
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.